A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Latest Information Update: 04 Jun 2025
At a glance
- Drugs HB 0052 (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Huaota Biopharmaceuticals
Most Recent Events
- 04 Jun 2025 New trial record